POD24 in follicular lymphoma: time to be "wise".

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.Signal transduction and targeted therapy · 2024
   Trial
2. Baseline FDG PET/CT SUVmax predicts POD24 and progression-free survival in newly diagnosed follicular lymphoma.Annals of nuclear medicine · 2026
   Article
3. Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study.HemaSphere · 2026
   Article
4. Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China.Frontiers in pharmacology · 2026
   Article
5. Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?Cancers · 2025
   Review
6. A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma.Biomarker research · 2025
   Article
7. Clinical-Demographic Profile, Prognostic Factors and Outcomes in Classic Follicular Lymphoma Stratified by Staging and Tumor Burden: Real-World Evidence from a Large Latin American Cohort.Cancers · 2024
   Article
8. Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival.International journal of molecular sciences · 2023
   Article
9. Update on follicular lymphoma.Hematological oncology · 2023
   Review
10. Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma.World journal of clinical oncology · 2023
    Review
11. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article

Corrections and comments

• Comment on
  Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as